I. Industry demand analysis    

       With the aging and the growth of people's demand for medicines, pharmaceutical equipment market has great potential.

       At the same time, with the accelerated transformation and upgrading of the pharmaceutical industry, the pharmaceutical manufacturing industry ushered in the growth of fixed asset investment.

       In the past, the domestic pharmaceutical machine market, especially the high-end market is basically dependent on imported equipment. After ten years of industrial chain development, domestic pharmaceutical equipment enterprises gradually become China's high-end manufacturing segments, domestic substitution accelerated, export overseas business growth, the industry gradually faded from the cycle attributes, ushering in long-term growth.

       In recent years, the pharmaceutical machine event can also be seen, pharmaceutical equipment in the field of "domestic power" is increasingly rising.

       It is worth noting that, after many years of rapid development, the domestic pharmaceutical equipment industry development is more and more robust, but still faces many challenges.

       In addition, China's pharmaceutical equipment products are still mainly low-end, Jiangsu Province, there are a lot of low-end pharmaceutical equipment enterprises, only Changzhou region, there are more than 600, compared with imported equipment, China's pharmaceutical manufacturing enterprises in the production technology, equipment levels, production processes, etc. There is a large gap.

       In September 2020, the Development and Reform Commission and other four departments jointly issued "on expanding investment in strategic emerging industries, cultivate and strengthen new growth points, growth poles of the guiding opinions", which puts forward to focus on supporting high-end medical equipment and pharmaceutical equipment and other high-end equipment production, the implementation of intelligent manufacturing, intelligent construction pilot demonstration. For the pharmaceutical equipment industry, the release of the heavyweight documents, will be conducive to boosting the domestic pharmaceutical machine industry towards the direction of high-end development.

       In general, from low-end production to high-end manufacturing is a major development trend in the pharmaceutical machine industry. However, there is still a long way to go for domestic medicine machines to go high-end.

       CHANSE technology since its inception to adhere to scientific and technological innovation, to China to replace imports of manufacturing. At present, the company has invested a lot of money in research and development, and continue to maintain a high level of investment in the fluidized bed market share has ranked among the top three in China, with the results of research and development work into the promotion of China's high-end pharmaceutical equipment to go first in the world.

II. Project implementation basis

1. Declaration of Basic Information of Applying Unit

(1) Main business of the company

       The main business of CHANSE Technology is the research and development, design and manufacture of solid dosage process equipment, as well as the provision of pharmaceutical process mapping, optimization, transfer of a full set of pharmaceutical solid dosage professional solutions. The main products of the company include: multi-functional fluidized bed (high quality), wet mixing granulator (high quality), dry granulator, extrusion and rounding machine, coating machine, tablet press and so on.

      (2) The main advantages of the enterprise in the industry

       At the beginning of its establishment, CHANSETechnology was determined to replace imports with Chinese manufacturing.

       CHANSE Technology is the deputy director unit of Intelligent Pharmaceutical Equipment Specialized Committee of China Chemical Pharmaceutical Industry Association, the standing committee member unit of Intelligent Manufacturing Specialized Committee of China Association of Traditional Chinese Medicine, the director unit of Pharmaceutical Technology Specialized Committee of China Association of Pharmaceutical Education, and there are co-built laboratories with China Pharmaceutical University, Shenyang Pharmaceutical University, and Xiangya School of Pharmacy of Hunan University.

       CHANSE Technology is the pioneer and leader of PAT technology and high containment technology in the domestic pharmaceutical industry. The company is also the world's first, epoch-making pharmaceutical method - continuous manufacturing, data release practitioners.

       The company established the process department in 2008, and in 2017, based on the process department, established Changzhou Oral Solid Intelligent Process Engineering Technology Research Center.

       According to the experimental data as well as customer feedback, the main performance of CHANSE equipment has reached the international advanced level, and it has been ahead of imported equipment in the field of traditional Chinese medicine, while the price is only one-third of imported equipment, which is very cost-effective, and the customers have a high degree of satisfaction and trust in the company.

      (3) Ratio of sales revenue and R&D investment to sales revenue in the previous year  

       Benefiting from the company's substantial investment in R & D, CHANSE equipment has become increasingly well-known in the field of drug solid dosage, but due to the impact of the epidemic in 2020, the sales revenue did not grow significantly that year.